Arcellx's anito-cel shows promising efficacy and safety in multiple myeloma. Read why I maintain my hold rating for ACLX ...

A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in ...

AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...

After experiencing unexplained symptoms, I was diagnosed with multiple myeloma and underwent a stem cell transplant.

Simcere Zaiming will receive an upfront payment from AbbVie and is eligible to receive option fees and milestone payments of ...

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in ...

A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a ...

Even before that deal, AbbVie had been showing an interest in the modality, with then-CEO Richard Gonzalez telling analysts ...

A CD38 monoclonal antibody, Sarclisa binds to a specific epitope on the CD38 receptor on myeloma cells, ultimately inducing ...

Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa and the standard treatment Pd, improved ...

Ladenburg, Germany, 13 January 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing ...